LivaNova PLC
Financials
Valuation Metrics
LivaNova PLC's Market Cap is $4.41B. At end of 2025 it was $3.35B. Ranked #1417 of 3,115 in US market (top 45%), #489 of 1,472 on NASDAQ (top 33%), #93 of 203 in Health Care Equipment & Services (top 46%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $4.41B | US#1,417/3,115 Sec#93/203 |
| Revenue | $1.47B | US#1,627/3,115 Sec#100/203 |
| Net Income | $189M | US#1,307/3,115 Sec#63/203 |
| Total Assets | $2.64B | US#1,896/3,115 Sec#93/203 |
| Net Assets | $1.33B | US#1,567/3,115 Sec#84/203 |
| Employees | 3,300 | US#1,427/3,115 Sec#101/203 |
| Value | ||
| P/E | 23.38x | US#1,333/3,115 Sec#37/203 |
| P/B | 3.33x | US#1,882/3,115 Sec#102/203 |
| P/S | 3.00x | US#1,713/3,115 Sec#115/203 |
| EV/EBITDA | 23.49x | US#2,048/3,115 Sec#96/203 |
| FCF Yield | 3.36% | US#1,738/3,115 Sec#97/203 |
| Profitability | ||
| ROE | 14.23% | US#946/3,115 Sec#47/203 |
| ROA | 7.14% | US#771/3,115 Sec#47/203 |
| Op. Margin | 13.48% | US#1,301/3,115 Sec#48/203 |
| Revenue Growth | 12.39% | US#1,060/3,115 Sec#73/203 |
| Financial Health | ||
| Debt Ratio | 99.26% | US#1,091/3,115 Sec#104/203 |
| Total Debt | $352M | US#2,036/3,115 Sec#109/203 |
| FCF | $148M | US#1,549/3,115 Sec#90/203 |
| Cash | $517M | US#1,051/3,115 Sec#60/203 |
| Current Ratio | 1.45x | US#1,709/3,115 Sec#153/203 |
| Net Debt/EBITDA | -0.91x | US#298/3,115 Sec#23/203 |
| Performance | ||
| 1Y Return | 52.52% | US#469/3,115 Sec#46/203 |
| 1M Return | 6.93% | US#1,095/3,115 Sec#110/203 |
| From 52W High | -6.40% | US#479/3,115 Sec#55/203 |
| 1Y MDD | -18.89% | US#567/3,115 Sec#14/203 |
| Trading | ||
| Volume | 506,460 shares | US#2,230/3,115 Sec#159/203 |
| Trading Value | $41M | US#1,626/3,115 Sec#114/203 |
| Per Share | ||
| EPS | $3.43 | US#969/3,115 Sec#52/203 |
| BPS | $24.13 | US#1,072/3,115 Sec#64/203 |
Company Info
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannulae, and other related accessories, as well as services related products. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals; and devices that deliver neuromodulation therapy for treating drug-resistant epilepsy and difficult-to-treat depression. This segment also includes the development and clinical testing of LivaNova's aura6000 system for treating obstructive sleep apnea. It serves perfusionists, neurologists, neurosurgeons, and other healthcare professionals, hospitals, and other medical institutions and healthcare providers. The company sells its medical devices through a combination of direct sales representatives, agents, and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.